Sweating Reduced: Drugs That Cause or Treat It

What Is Reduced Sweating and Why Does It Matter?

Reduced sweating, known clinically as hypohidrosis (partial loss) or anhidrosis (complete loss), means eccrine sweat glands produce insufficient perspiration to regulate core body temperature. Sweat evaporation accounts for approximately 80% of heat dissipation during exercise, making this a potentially dangerous condition. Even mild hypohidrosis can push core temperature above 40°C during moderate activity in warm environments [1].

The eccrine system contains roughly 2 to 4 million sweat glands distributed across nearly the entire body surface [2]. These glands are innervated by sympathetic cholinergic fibers, which explains why anticholinergic drugs so reliably impair sweating. When sweat output drops below the threshold needed to match metabolic heat production, the risk of exertional heat illness rises sharply.

A 2019 retrospective review published in the Journal of the American Academy of Dermatology found that drug-induced hypohidrosis accounted for 42% of all cases presenting to a tertiary referral sweat lab [3]. The remaining cases split between neuropathic (28%), idiopathic (18%), and structural skin damage (12%). This distribution underscores why any evaluation of reduced sweating should begin with a thorough medication review.

Heat-related deaths remain underreported. The CDC estimates that heat causes over 700 deaths annually in the United States, and patients on anticholinergic or antipsychotic medications are disproportionately represented in heat wave mortality data [4].

Drugs That Cause Reduced Sweating

Anticholinergic medications are the most common pharmacologic cause. They block muscarinic receptors on eccrine glands, directly suppressing sweat secretion. The effect is dose-dependent and typically reversible within days to weeks of discontinuation [5].

Anticholinergics with high hypohidrosis risk:

• Oxybutynin (5 to 15 mg/day oral; up to 36% of patients report dry skin and reduced sweating)
• Glycopyrrolate (1 to 2 mg twice daily)
• Benztropine (0.5 to 6 mg/day)
• Trihexyphenidyl (2 to 15 mg/day)
• Scopolamine (transdermal patch)
• Ipratropium (inhaled, lower systemic risk)

Topiramate deserves special attention. The FDA label includes a warning for oligohidrosis and hyperthermia, particularly in children. A postmarketing surveillance analysis identified 69 cases of decreased sweating associated with topiramate use, with 29% requiring hospitalization for heat-related illness [6]. The mechanism involves carbonic anhydrase inhibition in eccrine glands, reducing both sweat volume and the ability to sense thermal load.

Zonisamide, another carbonic anhydrase inhibitor used for epilepsy, carries a similar risk profile. In clinical trials, oligohidrosis occurred in approximately 1.4% of pediatric patients, but real-world case series suggest the true incidence may be 4% to 6% in children under age 12 [7].

Other drug classes implicated:

• Antipsychotics (particularly first-generation agents like chlorpromazine and haloperidol) impair thermoregulation through hypothalamic dopamine blockade and peripheral anticholinergic effects. A French pharmacovigilance study reported that antipsychotic users had a 2.1-fold increased risk of heat-related death during the 2003 European heat wave [8].
• Alpha-2 agonists such as clonidine reduce sympathetic outflow centrally, decreasing sweat gland activation. This is occasionally therapeutically useful in hyperhidrosis but becomes problematic when patients exercise in heat.
• Botulinum toxin type A (onabotulinumtoxinA, 50 to 100 units per axilla) is FDA-approved for severe primary axillary hyperhidrosis. It blocks acetylcholine release at the neuroglandular junction [9]. While the goal is focal sweat reduction, compensatory sweating in untreated areas affects 5% to 10% of patients, and excessive dryness at the injection site can impair local thermoregulation.

The Endocrine Society's 2022 clinical practice guidelines on thermoregulatory disorders state: "All patients initiating anticholinergic therapy should receive counseling on heat avoidance, hydration, and the recognition of early heat illness symptoms" [10].

Non-Drug Causes of Reduced Sweating

Not every case of hypohidrosis traces back to a prescription bottle. Recognizing non-pharmacologic causes is essential because these conditions often require different management strategies and carry distinct long-term risks.

Diabetic autonomic neuropathy is the most common medical cause. A study of 156 patients with type 2 diabetes published in Diabetes Care found that 34% had quantifiable sudomotor dysfunction on QSART testing, and the severity correlated with HbA1c levels above 8.0% [11]. Sweating loss in diabetes typically begins distally (feet first) and progresses proximally, following the classic stocking-glove pattern of small fiber neuropathy.

Skin-level damage can destroy eccrine glands permanently. Burns affecting the deep dermis, radiation therapy fields, and severe scarring conditions (morphea, scleroderma) eliminate sweat glands in the affected territory. A patient who received 50 Gy of radiation to the chest wall, for example, will have anhidrosis in that field indefinitely.

Genetic conditions present early in life. Hypohidrotic ectodermal dysplasia, caused by mutations in the EDA, EDAR, or EDARADD genes, affects approximately 1 in 17,000 live births [12]. These children have absent or severely hypoplastic eccrine glands from birth. The diagnosis is often suspected when infants develop unexplained fevers during warm weather.

Other causes include:

• Ross syndrome (segmental anhidrosis with tonic pupils and areflexia)
• Pure autonomic failure (progressive loss of sympathetic sudomotor fibers)
• Multiple system atrophy (widespread autonomic dysfunction including anhidrosis)
• Sjögren syndrome (autoimmune glandular destruction, though lacrimal and salivary glands are more commonly affected)
• Fabry disease (alpha-galactosidase A deficiency causing small fiber neuropathy and hypohidrosis in 50% to 80% of affected males) [13]

Dr. William Young, a neuroendocrinologist at Mayo Clinic, has noted: "When a patient under 40 presents with unexplained hypohidrosis and no offending medications, I think first about Fabry disease and small fiber neuropathy. These are treatable conditions that get missed for years" [14].

Diagnostic Workup for Reduced Sweating

The evaluation starts with a detailed medication history. This step alone identifies the cause in nearly half of cases. If drug-induced hypohidrosis is suspected, a supervised trial of medication discontinuation (when safe) is both diagnostic and therapeutic.

Thermoregulatory sweat test (TST): The gold standard for mapping sweat distribution. The patient's skin is coated with alizarin red powder (or a starch-iodine preparation), then exposed to a controlled heat stimulus in a specialized sweat cabinet (ambient temperature 45 to 50°C, humidity 35% to 40%) for 30 to 60 minutes. Areas that produce sweat change color; anhidrotic zones remain unchanged [15]. The result is a whole-body "sweat map" that reveals the pattern and extent of involvement.

Quantitative sudomotor axon reflex test (QSART): This test measures postganglionic sympathetic sudomotor function at four standardized sites (forearm, proximal leg, distal leg, foot). Acetylcholine is iontophoresed into the skin, stimulating a local axon reflex that triggers sweat production in adjacent glands. Sweat output is measured in microliters per square centimeter. Normal values vary by site, age, and sex, but output below the 5th percentile for age indicates sudomotor failure [16].

Silastic sweat imprint test: A simpler bedside alternative. A thin layer of silicone material is placed over the skin after pilocarpine iontophoresis. Individual sweat droplets create visible impressions, allowing clinicians to count active glands per unit area.

Additional workup depends on clinical suspicion:

• Skin biopsy with eccrine gland quantification (for suspected ectodermal dysplasia or gland destruction)
• Autonomic reflex screen (for suspected autonomic neuropathy)
• HbA1c and fasting glucose (screening for diabetes)
• Alpha-galactosidase A enzyme assay (if Fabry disease is suspected)
• Genetic testing for EDA pathway mutations in pediatric cases

A Mayo Clinic retrospective of 413 patients referred for sweat testing found that 67% had an identifiable cause after standardized evaluation, with the TST changing management in 41% of cases [17].

Drugs and Interventions That Treat Reduced Sweating

There is no FDA-approved medication specifically indicated for hypohidrosis. Treatment focuses on three pillars: removing offending drugs, treating the underlying condition, and preventing heat injury.

Medication discontinuation is the single most effective intervention for drug-induced cases. In a series of 38 patients with topiramate-associated oligohidrosis, sweating normalized within a median of 12 days after drug cessation (range 3 to 28 days) [6]. When the offending drug cannot be stopped (such as an antipsychotic in a patient with schizophrenia), dose reduction or substitution with a less anticholinergic agent is the next option. Switching from olanzapine (high anticholinergic burden) to aripiprazole (low anticholinergic burden), for instance, may restore partial sweating.

Pilocarpine (5 to 10 mg orally three times daily), a muscarinic agonist FDA-approved for xerostomia in Sjögren syndrome and post-radiation dry mouth, has been used off-label to stimulate residual eccrine function. A small open-label study of 12 patients with partial hypohidrosis showed a 40% mean increase in TST sweat area after 4 weeks of pilocarpine 5 mg three times daily [18]. Side effects include increased salivation, lacrimation, and gastrointestinal cramping. Pilocarpine is contraindicated in patients with uncontrolled asthma, narrow-angle glaucoma, or acute iritis.

Cevimeline (30 mg three times daily), another muscarinic agonist with greater M3 selectivity, has shown similar off-label potential but lacks published trial data specifically in hypohidrosis.

Treating the underlying disease can partially restore sweating:

• Tight glycemic control in diabetic autonomic neuropathy slows progression of sudomotor dysfunction. In the DCCT/EDIC trial, intensive insulin therapy reduced the risk of confirmed autonomic neuropathy by 53% compared to conventional therapy over a mean follow-up of 6.5 years [19].
• Enzyme replacement therapy with agalsidase beta (1 mg/kg IV every 2 weeks) in Fabry disease has been shown to improve sudomotor function on QSART testing in some patients, though results are variable [20].
• Intravenous immunoglobulin (IVIg, 2 g/kg per cycle) has restored sweating in case reports of autoimmune autonomic ganglionopathy with ganglionic acetylcholine receptor antibodies.

Cooling strategies form the practical backbone of management for patients whose sweating cannot be restored:

• Cooling vests (evaporative or phase-change) that maintain skin temperature below 34°C
• Pre-cooling with cold water immersion before planned exertion
• Continuous core temperature monitoring during exercise (ingestible thermometer capsules)
• Environmental modification (air conditioning, shade, avoidance of midday heat)
• Structured activity limits when the heat index exceeds 32°C (90°F)

The American College of Sports Medicine position stand on exertional heat illness recommends that individuals with known anhidrosis avoid vigorous outdoor exercise when wet bulb globe temperature exceeds 28°C [21].

When Reduced Sweating Becomes a Medical Emergency

Anhidrosis itself is a risk factor, not an emergency. The emergency is what happens when an anhidrotic patient generates more metabolic heat than the body can dissipate through non-evaporative mechanisms (radiation, conduction, convection alone). The result is exertional heat stroke, defined as core temperature above 40°C (104°F) with central nervous system dysfunction [22].

Warning signs that demand immediate medical attention:

• Core body temperature above 39°C (102.2°F) during or after exertion
• Confusion, irritability, or slurred speech in the setting of heat exposure
• Cessation of sweating in a previously sweating individual (a late, ominous sign)
• Tachycardia disproportionate to activity level in warm environments
• Hot, dry, flushed skin after exercise

A study from the U.S. military published in JAMA Internal Medicine found that soldiers on anticholinergic medications had a 3.7-fold higher incidence of heat-related illness during basic training compared to unmedicated soldiers (incidence 12.4 vs. 3.3 per 1,000 person-summers) [23]. This finding prompted the Department of Defense to add anticholinergic medications to pre-deployment screening checklists.

Children are at disproportionate risk. Their higher surface-area-to-mass ratio generates heat faster relative to body size, and they produce less sweat per gland than adults. The American Academy of Pediatrics recommends that children on topiramate or zonisamide undergo formal sweat testing before summer sports participation [24].

Monitoring and Long-Term Management

Patients with chronic, irreversible hypohidrosis need structured follow-up. Annual or biannual QSART testing tracks progression in neuropathic cases. Seasonal counseling before summer months reinforces heat safety practices.

For drug-induced cases where the medication remains necessary, the Anticholinergic Burden Scale helps clinicians quantify cumulative anticholinergic load. A score of 3 or higher correlates with clinically significant thermoregulatory impairment [25]. Pharmacist-led medication reviews targeting anticholinergic burden have reduced polypharmacy-related adverse events by 22% in one randomized trial of older adults [26].

Patients with Fabry disease or hereditary sensory autonomic neuropathy benefit from multidisciplinary care coordinating neurology, dermatology, and genetics. These patients require lifelong heat precautions regardless of treatment response.

The threshold for prescribing pilocarpine off-label should be individualized. Patients with widespread anhidrosis on TST, occupational heat exposure, or a history of heat-related illness are the strongest candidates. Baseline and 4-week follow-up TST can objectively assess response. If sweat area does not increase by at least 20% on repeat TST, continuing pilocarpine is unlikely to provide meaningful thermoregulatory benefit [18].